Analysts’ views on Sanofi
Sanofi (SNY) is scheduled to announce its earnings results for the second quarter of fiscal 2018 on July 31. The company is a global pharmaceuticals player with products and therapies across the specialty areas of oncology, immunology, vaccines, multiple sclerosis, rare disease disorders, neurology, cardiovascular diseases, diabetes, and infectious diseases.
Let’s look at analysts’ recommendations for SNY stock ahead of its Q2 2018 earnings results.
As of July 25, according to a recent Reuters survey, two of the five analysts covering SNY stock have given it a “strong buy” recommendation, and three have rated it a “hold.” There are no “sell” ratings.
These analysts have a target price of $44 for SNY stock, implying an upside potential of ~1.9% for the next 12 months. The return is based on SNY’s July 24 closing price of $42.63.
Analysts’ average consensus target prices for Sanofi’s peers Eli Lilly (LLY), Novo Nordisk (NVO), and GlaxoSmithKline (GSK) are $94.53, $60.40, and $41.74, respectively, implying -2%, 3%, and 18.2% returns, respectively, over the next 12 months.
Recent ratings and target price updates
On July 19, Deutsche Bank cut its target price for Sanofi from 88 euros to 87 euros for the French listing of the stock. However, on July 13, Jefferies raised its target price for Sanofi. It has a “hold” rating on the stock.
Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data, as well as dividend information. Take a look!